nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-7000DBE9·Framework v5.13·Pipeline v0.4·Evaluated 20 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Clinical Neurology·Basis: Full text·Type: Randomized controlled trial

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial

Michael D Jenkinson et al.Michael D Jenkinson, Anna Rosala-Hallas, Felix Sahm et al.·2026·The Lancet·10.1016/s0140-6736(26)01804-0 ↗

Primary claim

Disease-free survival was improved in the radiotherapy group compared with the observation group (hazard ratio 0·51 [95% CI 0·27–0·97]; p=0·0396).

Supported · randomised ITT evidence with unmasked local imaging assessment, fewer events than planned, and an imprecise effect estimate
In brief

Randomised evidence supports adjuvant radiotherapy after complete atypical meningioma resection, but imprecision limits certainty about the benefit’s magnitude.

ReliabilityCaveats4 of 4 checks completeErratum published 21 Nov 2026 and 1 moreRead the entry ↓
Possible — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: WHO grade 2 atypical meningioma is a primary brain tumour with a high risk of recurrence even after complete surgical resection. The role of adjuvant radiotherapy remains uncertain. We aimed to assess whether adjuvant radiotherapy reduces recurrence compared with observation in patients with a newly diagnosed atypical meningioma who have undergone complete surgical resection. METHODS: ROAM/EORTC-1308 was an international, multicentre, open-label, phase 3, randomised controlled trial, conducted at 58 hospitals and academic centres in 11 countries. Eligible sites had appropriate multidisciplinary expertise, neurosurgery, and radiotherapy facilities. Patients aged 16 years or older who had undergone a surgeon-assessed complete surgical resection of newly diagnosed atypical meningioma were randomly assigned (1:1) to adjuvant radiotherapy or observation. Randomisation was done using a web-based interface using random variable blocks of sizes two and four, stratified by location (UK or non-UK). Participants assigned to the radiotherapy group received fractionated external-beam intensity-modulated radiotherapy at a total dose of 60 Gy in 30 fractions over 6 weeks. Participants were followed up for a minimum of 4 years. The primary outcome was disease-free survival, defined as time from surgery to MRI-confirmed recurrence or death due to any cause, analysed in all randomly assigned participants in their assigned treatment group. Harms analysis was done in the as-treated population. The trial was registered with ISRCTN, ISRCTN71502099, and has completed. FINDINGS: Between April 28, 2016, and May 21, 2021, 990 patients were assessed for eligibility, 157 of whom were randomly assigned to radiotherapy (n=78) or observation (n=79). Median age was 57·40 years (IQR 49·09-66·93); 84 (54%) participants were female and 73 (46%) were male. At a median follow-up of 64 months (IQR 50-75), meningioma recurrence occurred in 11 (14%) of 78 participants in the radiotherapy group and 24 (30%) of 79 in the observation group. 5-year disease-free survival was 79·9% (95% CI 67·6-87·9) in the radiotherapy group and 64·3% (51·9-74·2) in the observation group (absolute difference 15·6% percentage points [95% CI 0·6-30·5]). Disease-free survival was improved in the radiotherapy group compared with the observation group (hazard ratio 0·51 [95% CI 0·27-0·97]; p=0·0396). Grade 2 or 3 radiation-related serious adverse events occurred in five (8%) of 66 participants in the radiotherapy group, with no treatment-related deaths. INTERPRETATION: Our findings suggest that adjuvant radiotherapy should be considered in patients with atypical meningioma after complete surgical resection of atypical meningioma when the prevention of recurrence is valued higher than the potential delayed adverse effects of radiotherapy. This practice will benefit patients by reducing meningioma recurrence. Decisions should be based on individual discussion with the patient. FUNDING: National Institute for Health and Care Research Health Technology Assessment programme, the European Organisation for Research and Treatment of Cancer Brain Tumour Group and Radiation Oncology Group, and the Heath Research and Medical Research Council of Australia.

Key Claims

Primary finding · Supported

Disease-free survival was improved in the radiotherapy group compared with the observation group (hazard ratio 0·51 [95% CI 0·27–0·97]; p=0·0396).

Possible — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

randomised ITT evidence with unmasked local imaging assessment, fewer events than planned, and an imprecise effect estimate

Abstract, Findings; Results
Quote verified
Secondary · Tentative

Adjuvant fractionated radiotherapy halves the risk of recurrence, regardless of methylation class, and with minimal late toxicity.

post-hoc as-treated molecular adjustment without demonstrated subgroup interactions cannot establish benefit regardless of methylation class

Discussion, final paragraph
Quote verified
Secondary · Tentative

There were no between-group differences in health-related quality of life or neurocognitive function and there was minimal radiation toxicity.

substantial secondary-outcome missingness and unblinded patient reporting prevent firm conclusions about absence of detriment

Research in context, Added value of this study
Quote verified
Secondary · Supported

Grade 2 or 3 radiation-related serious adverse events occurred in five (8%) of 66 participants in the radiotherapy group, with no treatment-related deaths.

systematic harms reporting supports the counts despite as-treated, open-label ascertainment

Abstract, Findings; Results; Table 2
Quote verified
Secondary · Unsupported

[Early radiotherapy-related adverse events] were expected and all were mild (grade 1 or 2).

the reported early grade 3 radiation-related seizure contradicts universal grade 1-or-2 severity

Discussion, adverse effects
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Randomised evidence addresses a treatment uncertainty

The comparison with observation directly informs postoperative management after complete resection of atypical meningioma, extending evidence previously drawn from retrospective cohorts and non-randomised phase 2 studies.

↳ Introduction; Research in context; Discussion, prior trials

#methodological rigour

Prospective central review supports treatment consistency

Participating centres completed benchmark planning cases, and individual radiotherapy plans required central approval before treatment. Web-based randomisation and ITT analysis further support the primary comparison.

↳ Methods, Randomisation and masking, Procedures, Statistical analysis

#positioning

Clinical interpretation explains reasons to defer

The Discussion notes that 70% of observed participants remained recurrence-free and identifies clinical circumstances in which deferring radiotherapy remains reasonable.

↳ Discussion, clinical interpretation and treatment trade-offs

Limitations

#positioning

Molecular independence exceeds the exploratory evidence

The conclusion asserts benefit regardless of methylation class, although molecular analyses were post-hoc, as-treated, and restricted to available tissue. Adjusted treatment estimates do not establish benefit in every molecular subgroup.

↳ Methods, molecular statistical analysis; Results, molecular analyses; Discussion, final paragraph

#methodological rigour

Incomplete unblinded outcomes limit reassurance claims

Only 38% contributed five-year HRQoL data, and approximately 45% of 24-month cognitive assessments were missing. Unblinded patient reporting adds uncertainty, making the summary-box assertion of no differences too definitive.

↳ Methods, masking and Outcomes; Results, secondary outcomes; Research in context, Added value

#methodological rigour

Safety narrative contradicts reported serious events

The Discussion calls all early symptoms grade 1 or 2 despite reporting an early grade 3 radiation-related seizure. The Results also describe six serious events among nine observation-group participants, an impossible count as written.

↳ Discussion, adverse effects and serious adverse events; Results, serious adverse events

Does this match your read? Add your assessment ↓

Nabu Commentary

The trial provides direct randomised evidence for postoperative radiotherapy, supported by ITT analysis and prospective central treatment-plan review. The primary estimate remains imprecise, with 41 rather than 46 planned events and an as-treated interval crossing the null. Extensive missing secondary data constrain reassurance about quality of life and cognition, while exploratory molecular adjustment does not establish efficacy regardless of methylation class. Although the Discussion describes meaningful treatment trade-offs, its stronger concluding language and contradictory safety narrative reduce confidence in those interpretations without invalidating the primary efficacy calculation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.7±0.1

Contribution
4.3

The randomised comparison supplies direct evidence for a treatment decision previously informed by retrospective and non-randomised studies. The advance remains bounded by an imprecise primary estimate and unresolved molecular and patient-reported conclusions.

Introduction; Research in context; Results, primary outcome; Discussion, comparison with phase 2 trials
Methodological Rigour
3.8

Central randomisation, ITT analysis, sensitivity analyses, and prospective radiotherapy-plan review support the primary comparison, while event shortfall, unmasked assessment, and incomplete secondary outcomes constrain execution. The contradictory early-safety description and impossible observation-group serious-event count are surfaced through the reliability flag without imposing a reliability cap.

Methods, Randomisation and masking, Procedures, Statistical analysis; Results, efficacy and adverse events; Table 2
Reporting
3.6

The manuscript distinguishes assigned-group, as-treated, and exploratory analyses and reports both absolute and relative effects. The prominent assertion of no quality-of-life or cognitive differences communicates greater certainty than the incomplete data support.

Abstract; Research in context, Added value; Results, HRQoL and neurocognitive outcomes
Positioning
2.8

The Discussion engages conflicting prior studies and concrete reasons to defer radiotherapy. Its concluding claim of benefit regardless of methylation class nevertheless exceeds the acknowledged exploratory molecular evidence.

Methods, molecular statistical analysis; Discussion, prior evidence, limitations, and final paragraph

Lower confidence on Methodological Rigour, Reporting — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • "Although almost half the patients reported new symptoms, these were expected and all were mild (grade 1 or 2)." (Discussion, adverse effects) vs "a grade 3 seizure and a grade 2 headache, both of which the patients recovered from." (Discussion, serious adverse events). The universal grade 1-or-2 description of early symptoms is contradicted by the explicitly reported early grade 3 radiation-related serious seizure. The claim is not supported by the paper's own data.
  • "events were mild, and there were no grade 3 or" (Discussion, paragraph on adverse events) vs "Grade 2 or 3 radiation-related serious adverse events occurred in five (8%) of 66 participants" (Abstract, Findings). The broad no-grade-3 wording conflicts with the separately reported grade 3 serious event, but does not invalidate the abstract's five-participant harms count. The result itself is unaffected.
Reporting and transparencyClean

Ethics approval, trial registration, competing interests, and controlled-access participant-data sharing are declared. No concern grounded in the supplied reporting establishes a research-conduct issue.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared

Reference IntegrityClean

38 references in manuscript 36 of 37 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Erratum published 21 Nov 2026 and 1 more · listed in Crossref

Last checked: 20 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Brain and central nervous system cancer
Type of advanceEmpirical
Route to useSpecified
AdvanceAdvances
BeneficiariesMedium
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A completed international multicentre phase 3 randomised controlled trial across 58 hospitals in 11 countries with 64 months median follow-up confirms the primary claim in an independent real-world setting.

From the paper
“ROAM/EORTC-1308 will inform national and international guidelines and adjuvant fractionated radiotherapy should be considered”

The paper names guideline bodies as actors and specifies the clinical decision setting: considering adjuvant fractionated radiotherapy after complete resection of atypical meningioma.

Pathway

National and international guideline bodies, and neuro-oncology multidisciplinary teams, adopt adjuvant fractionated radiotherapy as standard post-operative management for completely resected atypical meningioma.

Barrier

Uncertain long-term toxicity beyond 5 years, a pending cost-effectiveness analysis, and an underpowered event count leave guideline bodies and clinicians awaiting confirmatory evidence.

Evaluated 20 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Prevalence of chronic traumatic encephalopathy at death in National Football League players: retrospective population based cohort study, 2008-21

    2026 · Health sciences

    Primary claim

    At minimum, nearly a quarter of all former NFL players who died during 2016-21 had CTE neuropathology at death.

    Well-supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  2. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

    Selvaraj, Livesey, Zhao, et al. · 2018 · Basic medicine

    Primary claim

    increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  3. Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons

    Stavrou, Heffernan, Carter, et al. · 2026 · Basic medicine

    Primary claim

    human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs)

    Supported
    Evidence Score
    3.1±0.1
    Reliability
    Caveats

How the rubric works →